期刊文献+

线粒体DNA相关的药物不良反应及其防治 被引量:4

Mitochondrial DNA-related Adverse Drug Reactions and the Prevention Methods
下载PDF
导出
摘要 线粒体是细胞中能量储存和供给的场所,也是动物细胞核外唯一含有遗传效应物质的细胞器。线粒体DNA自身的结构特点使其容易受到损伤,其独立的复制表达系统往往可成为外源物质攻击的靶点。很多药物的不良反应均与mtDNA损伤有关。以抗逆转录病毒药物、抗肿瘤药物和抗生素为例,综述线粒体DNA相关药物不良反应及其相关机制,并对防治方法进行了探讨。 Mitochondrium, the place where the energy is stored and supplied, is the unique organelle which also has the genetic material outside the cellular nucleus of animals. Mitoehondrial DNA(mtDNA) is vulnerable to injury, and its independent replication/expression systems are also vulnerable to xenobiotics attacks due to its own structural feature. Many adverse drug reactions are related to mtDNA injury. The mtDNA-related adverse drug reactions caused by nucleoside reverse transeriptase inhibitors( NRTIs), antitumor drugs and antibiotic, as well as the related mechanisms were reviewed in this paper. The prevention and therapeutic methods against mtDNA-related drug adverse reactions were also discussed.
出处 《药学进展》 CAS 2010年第9期392-398,共7页 Progress in Pharmaceutical Sciences
基金 中医药行业科研专项(No.200707008) 十一五科技重大专项(No.2009ZX09302-002) 国家青年自然科学基金(No.30701106)
关键词 线粒体DNA 不良反应 核苷类逆转录酶抑制剂 抗肿瘤药 抗生素 防治 mitochondrial DNA adverse drug reaction nucleoside reverse transcriptase inhibitor antitumor drug antibiotic prevention and therapy
  • 相关文献

参考文献35

  • 1Schon E A.Mitochondrial genetics and disease[J].Trends Biochem Sci,2000,25(11):555-560.
  • 2Li X M,Guan M X.A human mitochondrial GTP binding protein related to tRNA modification may modulate phenotypic expression of the deafness-associated mitochondrial 12S rRNA mutation[J].Mol Cell Biol,2002,22(21):7701-7711.
  • 3Blaikie F H,Brown S E,Samuelsson L M,et al.Targeting dinitrophenol to mitochondria:limitations to the development of a self-limiting mitochondrial protonophore[J].Biosci Rep,2006,26(3):231-243.
  • 4Jones S P,Qazi N,Morelese J,et al.Assessment of adipokine expression and mitochondrial toxicity in HIV patients with lipoatrophy on stavudine-and zidovudine-containing regimens[J].J Acquir Immune Defic Syndr,2005,40(5):565-572.
  • 5White K L,Margot N A,Ly J K,et al.A combination of decreased NRTI incorporation and decreased excision determines the resistance profile of HIV-1 K65R RT[J].AIDS,2005,19(16):1751-1760.
  • 6Gerschenson M,Nguyen V,Ewings E L,et al.Mitochondrial toxicity in fetal Erythrocebus patas monkeys exposed transplacentally to zidovudine plus lamivudine[J].AIDS Res Hum Retroviruses,2004,20(1):91-100.
  • 7Christians U,Gottschalk S,Miljus J,et al.Alterations in glucose metabolism by cyclosporine in rat brain slices link to oxidative stress:interactions with mTOR inhibitors[J].Br J Pharmacol,2004,143(3):388-396.
  • 8Lim S E,Copeland W C.Differential incorporation and removal of antiviral deoxynucleotides by human DNA polymerase gamma[J].J Biol Chem,2001,276(26):23616-23623.
  • 9Walker U A,Venhoff N,Koch E C,et al.Uridine abrogates mitochondrial toxicity related to nucleoside analogue reverse transcriptase inhibitors in HepG2 cells[J].Antivir Ther,2003,8(5):463-470.
  • 10Eriksson S,Xu B,Clayton D A.Efficient incorporation of anti-HIV deoxynucleotides by recombinant yeast mitochondrial DNA polymerase[J].J Biol Chem,1995,270(32):18929-18934.

二级参考文献37

  • 1戴令娟,侯杰,蔡后荣,王伟,张道中.川芎嗪当归治疗肺间质纤维化的实验研究[J].中华结核和呼吸杂志,1996,19(1):26-28. 被引量:86
  • 2Bessen LJ, Greene JB, Louie E, et al. Severe polymyositis-like syndrome associated with zidovudine therapy of AIDS and ARC[J]. N Engl J Med, 1988, 318(11): 708.
  • 3Simpson DM, Slasor P, Dafni U, et al. Analysis of myopathy in a placebo-controlled zidovudine trial [ J ]. Muscle Nerve, 1997, 20(3) :382-385.
  • 4Peters BS, Winer J, Landon DN, et al. Mitochondrial myopathy associated with chronic zidovudine therapy in AIDS[J]. QJMed, 1993, 86(1):5-15.
  • 5Helbert M, Fletcher T, Peddle B, et al. Zidovudine-associated myopathy[J]. Lancet, 1988, 2(8612) :689-690.
  • 6Arnaudo E, Dalakas M, Shanske S, et al. Depletion of muscle mltochondrial DNA in AIDS patients with zidovudine-induced myopathy[ J ]. Lancet, 1991, 337 (8740) : 508 -510.
  • 7Klopstock T. Drug-induced myopathies [ J ]. Curr Opin Neurol, 2008, 21(5):590-595.
  • 8Masini A, Scotti C, Calligaro A, et al. Zidovudine-induced experimental myopathy: dual mechanism of mitochondrial damage[ J]. J Neurol Sci, 1999, 166 (2) :131- 140.
  • 9Scruggs ER, Dirks Naylor AJ. Mechanisms of zidovudineinduced mitochondrial toxicity and myopathy [ J ]. Pharmacology, 2008, 82 ( 2 ) : 83-88.
  • 10Kohler JJ, Lewis W. A brief overview of mechanisms of mitochondrial toxicity from NRTIs [ J ]. Environ Mol Mutagen, 2007, 48(34) :166-172.

共引文献63

同被引文献36

  • 1刘翠梅.线粒体病现状(综述)[J].临床儿科杂志,1995,13(6):413-414. 被引量:4
  • 2立彦,王自正.线粒体DNA的研究现状[J].国际检验医学杂志,2006,27(7):636-638. 被引量:7
  • 3穆荣,马志毅,袁云,栗占国.线粒体肌病误诊为炎性肌病一例[J].中华风湿病学杂志,2007,11(1):57-58. 被引量:2
  • 4Fang B, Xiao H.Rapamycin alleviates cisplatin-induced o-totoxicity in ^t2;o[J].Biochem Biophys Res Commun,2014,448(4):443-447.
  • 5Oh GS,Kim HJ,Choi J Hyet al.Pharmacological activationof NQ01 increases NAD+ levels and attenuates cisplatin-mediated acute kidney injury in mice[J].Kidney Int,2014,85(3):547-560.
  • 6Seidman MD,Bai U,Khan MJ,et al.Mitochondrial DNA dele-tion associated with aging and presbyacusis[J]Arch Otolaryn-gol Head Neck Surg, 1997,123(10) : 1039-1045.
  • 7Ding D,He J,Allman BL,et al.Cisplatin ototoxicity in ratcochlear organotypic cultures [J].Hear Res ,2011,282 (1 -2):196-203.
  • 8Chang J,Jung HH,Yang JY,e? ai.Protective effect of met-formin against cisplatin-induced ototoxicity in an auditorycell line[J].Assoc Res Otolaryngol,2014,15(2) : 149-158.
  • 9Goncalves MS,Silveira AF’Teixeira AR,et al.Mechanismsof cisplatin ototoxicity: theoretical review [J]Laryngol Otol,2013,127(6):536-541.
  • 10Murch N.Mitochondrial DNA mutations predispose to amino-glycoside induced ototoxicity[J].BMJ, 2012,345 : e7255.

引证文献4

二级引证文献17

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部